Global Botanical And Plant-Derived Drugs Market Set To Grow To $40.5 Bn By 2022

03 August 2018
Pharma

Visiongain has launched a new pharma report Botanical and Plant-Derived Drugs Market Forecast to 2027: Prospects for Leading Companies in Steroids, Phenols, Terpenes, Glycosides and Others, Sativex, Marinol Nabilone, Dexanabinol, CT-3, Cannabinor, HU 308, HU 331, Rimonabant, Taranabant
Plant derived substances have recently become of great interest owing to their versatile applications. Medicinal plants have been used for centuries as remedies for human diseases and offer a new source of biologically active chemical compound as antimicrobial agent. Medicinal plants are the richest bio-resources of drugs of traditional medicinal systems, modern medicines, nutraceuticals, food supplements, folk medicines, pharmaceuticals, intermediate and chemical entitled for synthetic drugs. It has been estimated that 14 - 28% of higher plant species are used medicinally and that 74% of pharmacologically active plant derived components were discovered after following up on ethno medicinal use of the plants. Botanical drugs are those drugs which are derived from medicinal plants. Plant derived drugs are combination of botanical as well as other approved drugs that contains plant materials, synthetic and semi synthetic substances.

The lead analyst of the report commented “There has been rising interest in botanical drugs, with many pharmaceutical companies investigating the commercial potential. The global botanical derived drugs market will experience steady growth over the forecast period.

Growth in the market is primarily driven by increasing focus on the development of drugs for new indications, increasing prevalence of various chronic diseases and public as well as private investment for botanical and plant derived drug. However, challenges in clinical trials and stringent laws and regulations for approval will deplete the market.”

Leading companies featured in the report include Abbott Laboratories, Bayer AG, Eli Lilly
Johnson & Johnson, Novartis AG, Pfizer, Inc., Bristol-Myers Squibb (BMS), Medigene AG

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes OTC Drugs & Dietary Supplements Market Report 2020-2030

The increasing rates of patent expiry lead to a counter-strategy of switching companies from Rx to OTC. In the US, according to the Consumer Healthcare Products Association, approximately 106 ingredients and dosage strengths have undergone a change from Rx to OTC to around 700 OTC products on the market.

23 September 2020

Read

Visiongain Publishes Healthcare Cold Chain Logistics Market Report 2020-2030

. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.

16 September 2020

Read

Visiongain Publishes Vaccines Sales Market Report 2020-2030

Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.

14 September 2020

Read

Visiongain Publishes Ophthalmic Ultrasound Systems Market Report 2020-2030

The global ophthalmic ultrasound systems market is driven by factors such as the increasing prevalence of ocular disorders and diseases, adoption of novel ophthalmic technologies, rising focus on research & development, and growing health awareness amongst the population.

09 September 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever